Overexpression of Eukaryotic Translation Initiation Factor 5A2 (EIF5A2) Correlates with Cell Aggressiveness and Poor Survival in Gastric Cancer

Qing-Bin Meng¹,², Wei-Ming Kang¹, Jian-Chun Yu¹,*, Yu-Qin Liu³, Zhi-Qiang Ma¹, Li Zhou¹, Quan-Cai Cui⁴, Wei-Xun Zhou⁴

¹ Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China, ² Department of Gastrointestinal Surgery, the First Hospital of Wu Han City, Wuhan city, Hubei Province, China, ³ Cell Center, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, Wuhan city, Beijing, China, ⁴ Department of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China

* yujch001@163.com

Abstract

Eukaryotic translation initiation factor 5A2 (EIF5A2) plays an important role in tumor progression and prognosis evaluation. However, little information is available about its potential role in gastric cancer. This study aimed to investigate the function of EIF5A2 in tumor progression and its potential mechanisms. EIF5A2 expression was measured in human gastric cancer cell lines, the immortalized gastric mucosal epithelial cell line (GES-1) and human gastric cancer tissues and knocked down by RNA interference or upregulated by EIF5A2 plasmid transfection. Cell proliferation, migration and invasion were assessed in vitro. The downstream targets of EIF5A2 were examined by western blotting. EIF5A2 and its potential target metastasis-associated protein 1 (MTA1) expression were examined in 160 pairs of human gastric cancer and adjacent non-tumor specimens using immunohistochemistry (IHC) staining, and its correlation with clinicopathological features and survival was investigated. Knockdown of EIF5A2 or MTA1 caused an apparent suppression of HGC27 cell proliferation, migration and invasion. After knockdown of EIF5A2 in HGC27 cells, E-cadherin levels were upregulated and vimentin, cyclin D1, cyclin D3, C-MYC and MTA1 levels were downregulated. Upregulation of EIF5A2 in MKN45 cells resulted in the converse. IHC results showed a positive correlation between EIF5A2 and MTA1 expression in gastric cancers (P<0.001). Both EIF5A2 and MTA1 overexpression were correlated with pT stage (P=0.018 and P=0.042), pN stage (P=0.037 and P=0.020) and lymphovascular invasion (P=0.016 and P=0.044). EIF5A2 or MTA1 overexpression was significantly associated with poor overall survival and disease-free survival (All P<0.05). Multivariate analyses identified EIF5A2 as an independent predictor for both overall survival (P=0.012) and disease-free survival (P=0.008) in gastric cancer patients. Our findings indicate that EIF5A2 upregulation...
plays an important oncogenic role in gastric cancer. EIF5A2 may represent a new predictor for poor survival and is a potential therapeutic target for gastric cancer.

**Introduction**

Gastric cancer (GC) is a highly metastatic disease and one of the most lethal of the gastrointestinal malignancies.[1] Despite advances in surgical and cytotoxic therapies for GC, the current treatments available to patients with advanced GC are very limited.[2, 3] To develop new therapeutic strategies, it is crucial to elucidate the molecular mechanisms that promote the invasive and metastatic properties of GC cells.

Eukaryotic translation initiation factor 5A2 (EIF5A2) is located at human chromosome 3q26.2, and is a member of the EIF5A gene family.[4] Overexpression of EIF5A2 mRNA in certain human cancer cells, in contrast to overexpression limited to human testis and parts of brain, suggests EIF5A2 is a potential oncogene.[4] Previous studies found that EIF5A2 was overexpressed in many human cancers such as pancreatic ductal adenocarcinoma, ovarian cancer, hepatocellular cancer, lung cancer, colorectal cancer and melanoma, and was correlated to poor survival of cancer patients and/or cancer cell aggressiveness.[5–11] Recent studies have demonstrated that EIF5A2 has carcinogenic abilities through its activation of the EIF5A2-MTA1/C-MYC axis.[8] However, little information is available about EIF5A2 protein expression, its prognostic significance and potential oncogenic role in human GC.

Accordingly, we first investigated the expression of EIF5A2 in human GC cell lines and its potential role in cell proliferation, migration and invasion. Next, we identified possible downstream target proteins to elucidate the impact of EIF5A2 depletion or upregulation on the cellular functions of GC cells. Finally, we analyzed the correlation of EIF5A2 and MTA1 expression in human GC and its relevance to clinicopathological factors and survival in GC patients.

**Materials and Methods**

**Ethics Statement**

The study was approved by the Ethics Committee of PUMCH, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China, and written informed consent was obtained from each patient.

**Patients and specimens**

GC tissue and matched adjacent non-tumor tissue samples were obtained from 160 consecutive patients who underwent surgical resection for primary GC at Peking Union Medical College Hospital (PUMCH) between January 2002 and December 2006. No patients received neoadjuvant chemotherapy or radiotherapy. The survival data were obtained based on both the patients’ records and telephone follow-up. The median follow-up time was 53 months (range, 1–113 months). Another two pairs of fresh GC tissues and noncancerous gastric mucosa tissues were obtained from patients who underwent surgical resection for poorly differentiated adenocarcinoma of stomach at PUMCH in 2014.

We defined lymphovascular invasion as the presence of tumor cell emboli within spaces surrounded by a clearly visualized endothelial lining in the periphery of tumor sections.[12, 13] Patients were staged according to the 7th edition of the AJCC TNM classification for
carcinoma of the stomach.[14] Lauren histotype was divided into intestinal and diffuse-mixed type categories.[15]

Cell culture

Five types of human GC cell lines were obtained from the Cell Center of Shanghai Institutes for Biological Sciences (AGS and MGC803, Shanghai, China) and the Cell Center of Institute of Basic Medical Sciences (MKN45, SGC7901 and HGC27, Beijing, China). The immortalized gastric mucosal epithelial cell line GES-1 was obtained from Beijing ComWin Biotech Co., Ltd (Beijing, China). All cells were cultured in RPMI 1640 medium supplemented with 10% fetal bovine serum (FBS; Life Technologies, Carlsbad, CA, USA) at 37°C in a humidified air atmosphere containing 5% CO2. Cells in logarithmic growth phase were used for further experiments.

Knockdown EIF5A2 or MTA1 by small-interfering RNAs (siRNAs)

The siRNA specifically against EIF5A2 and MTA1[16] and their non-targeting control siRNA (Life Technologies, Carlsbad, CA, USA) were chemically synthesized for this study. The EIF5A2 siRNA sequences were as follows: #1: 5'-GGAUUUAAACUGCCAGAAATT-3', 5'-UUCUAGCAGUUAAGACU CCTT-3'; #2: 5'-GGUUCACCUCUUGAUAUUTT-3', 5'-AAUCCCAACAAGGGUAACCTT-3'; and #3: 5'-GCUUCCACAGCUACUUCCCUATT-3', 5'-UAGGGUAAGUUGCGGAAGCTT-3'; the non-targeting control (NC1) siRNA: 5'-UUC UC GAA CGU GUC ACG UTT-3'; 5'-ACG UGA CAC GUU CGG AGA ATT-3'. The MTA1 siRNA sequences (Target 2 siRNA, T2-siRNA) were: 5'-GCUUAAAGCCUAGAGC CdtTdT-3', 5'-GCUUAAACUUGGCUCUCACGdCdtTdT-3') and FAM-labeled siRNA (AM4620) was used as a non-targeting control siRNA (NC2).

Twenty-four hours after plating in six-well plates, GC cells were transfected with 100pmol EIF5A2-siRNA, MTA1-siRNA or control siRNA using Lipofectamine 2000 transfection reagent (Life Technologies, Carlsbad, CA, USA) according to the manufacturer’s instructions. The cells were harvested for western blotting at 48 h after transfection.

Plasmid construction and transient transfection

EIF5A2 expression vector (PIRES2-EGFP-EIF5A2) was synthesized by Life Technologies. Cells were transfected with PIRE S2-EGFP-EIF5A2 or the control plasmid using Lipofectamine 2000 transfection reagent (Life Technologies, Carlsbad, CA, USA) according to the manufacturer’s instructions.

Real-time quantitative RT-PCR

Total RNA was isolated using TRizol Reagent (Life Technologies) according to the manufacturer’s protocol. PCR was performed using the sequences for EIF5A2: forward: 5' - AACTGC CAGAAGGGTGAAACTAGG-3' ; reverse: 5' - GTTTCCGT TATTGGCAGGGT-3' and the sequences for MTA1: forward: 5'-CCGGGGCTTGCGAGAGCTGGTACAC-3'; reverse: 5'-CACGGCATTCCAGCGTCTCAGTAC-3'. PCR was performed using UltraSYBR Mixture (CWbio.Co.Ltd) according to the manufacturer’s protocol. Reverse transcription was performed using a PrimeScript RT Master Mix kit (TAKARA Biotechnology Co. Ltd., Dalian, China). The cDNA products were subjected to real-time PCR using a SYBR Premix Ex Taq II kit (TAKARA Biotechnology Co. Ltd.). Real-time PCR was performed in a StepOnePlus Real-Time PCR System (Applied Biosystems, Carlsbad, CA) using the following program: 95°C for 10 minutes, followed by 40 cycles of 95°C for 15 seconds, and 60°C for 1 minute. GAPDH mRNA in each sample was quantified as an endogenous control.
Western blotting

Protein concentration was quantified using a BCA protein assay kit (Thermo Scientific Pierce). Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) was used to separate cell lysates. Proteins were transferred to PVDF membranes and blocked with tris-buffered saline and 0.1% Tween 20 (TBST) containing 5% bovine serum albumin, and then incubated with the following primary antibodies at 4°C overnight: rabbit anti-EIF5A2 or -C-MYC (1:1000; Epitomics, USA, Catalog # 5549–1 or 1472–1), rabbit anti-MTA1, -E-cadherin or -vimentin (1:1000; Cell Signaling, USA, Catalog # 5647, 3195 or 5741), or mouse anti-GAPDH (1:1000; Santa Cruz, Catalog # sc-25778). The membranes were washed three times with TBST and incubated with horseradish peroxidase (HRP)-conjugated anti-rabbit or anti-mouse secondary antibodies (1:3000; Santa Cruz, USA, Catalog# sc-2004 or sc-2005) for 1 h at room temperature. The protein bands were visualized using ECL detection reagents (Pierce, USA). The relative protein expression levels were normalized to GAPDH.

Cell proliferation assay

The proliferation of HGC27 and MKN45 cells was examined using a Cell Counting Kit-8 (CCK-8) (Dojindo, Japan) according to the manufacturer’s instructions. Briefly, 24 h after transfection with siRNA or plasmid, the cells were seeded at a density of 1x10^4 cells/well in 96-well plates and cultured for 0, 24, 48 and 72 h. Then, at the different time points, 10μL CCK-8 solution was added to each well and incubated for 2 h. The absorbance was read at 450nm on a plate reader.

Transwell assays

The migratory and invasive ability of GC cells was detected using 24-well transwell cell culture chambers (8.0μm pore size, Costar, Cambridge, MA, USA) according to the manufacturer’s instructions. For the cell invasion assay, the insert membranes were pre-coated with Matrigel (BD, San Diego, CA, USA). For the cell migration assay, no Matrigel was used. At 24 h post-transfection, the cells were seeded at an appropriate density (HGC27, 5x10^5/ml; MKN45, 1x10^7/ml) in the upper chamber and cultured in OPTI-MEM (GIBCO, USA) without FBS for a further 24 h. The cells were allowed to migrate towards the RPMI 1640 medium containing 20% FBS in the bottom chamber. The non-migratory cells on the upper membrane surface were removed with a cotton tip, and the migratory cells attached to the lower membrane surface were fixed with 4% paraformaldehyde and stained with H&E. The numbers of invaded cells were counted in five randomly selected fields under a microscope.

Immunohistochemistry (IHC) staining and assessment

IHC staining was performed on 5μm-thick sections from paraffin-embedded specimens. Monoclonal rabbit anti-human EIF5A2 antibody (Epitomics, USA, Catalog # 5549–1), rabbit anti-human MTA1 antibody (Cell Signaling, USA, Catalog # 5647) and PV-6000 Polymer Detection System (ZSBG-BIO, China) were used for staining in accordance with the manufacturer’s instructions. In brief, slides with paraffin sections were deparaffinized with xylene and rehydrated with ethanol. Endogenous peroxidase activity was blocked with 3% hydrogen peroxide for 10 min. For antigen retrieval, slides were microwave-treated and boiled in a 0.01M citrate buffer (pH 6.0) for 10 min, and thereafter incubated with 0.1% trypsin at 37°C for 5 min. The slides were incubated with monoclonal rabbit anti-human EIF5A2 or MTA1 antibody (1:100 dilution) for 1.5 h at 37°C in a humidified chamber. As a negative staining control, primary antibody was replaced with non-specific rabbit IgG. Two independent pathologists...
evaluated the immunohistochemical staining of EIF5A2 and MTA1. A semiquantitative scoring method was used with reference to the previous study.[7]

Statistical analysis
All analyses were performed using SPSS 12.0 software (Chicago, IL, USA). The McNemar test was used for comparison of EIF5A2 or MTA1 staining in human GC and adjacent non-tumor specimens. The chi-square test was used to compare differences between categorical variables, whereas the paired, two-tailed Student’s t-tests were used to compare differences between categorical variables. The correlation between EIF5A2 and MTA1 was analyzed using the Spearman’s rank test. For univariate survival analysis, survival curves were constructed using the Kaplan-Meier method and compared by the Log-rank test. The Cox proportional hazards model with multivariate analyses was used to investigate the independent prognostic factors. All P values were two-sided, and P values of <0.05 were considered to be statistically significant. All experiments were performed at least in technical and biological triplicates.

Results
EIF5A2 Expression in GC cells and tissues and validation of the intervention
We investigated the expression of EIF5A2 in five GC cell lines and the immortalized gastric mucosal epithelial cell line GES-1 in vitro by both qRT-PCR (Fig. 1A) and western blotting (Fig. 1B). EIF5A2 protein in human GC tissues was higher than that of the paired distant non-tumor tissues (Fig. 1C). Because of the high endogenous expression level of EIF5A2 and the relatively high transfection efficiency in HGC27, we selected this cell line for RNAi analysis, and selected MKN45 cells for EIF5A2 upregulation experiments due to its relatively low EIF5A2 expression and high transfection efficiency.

All three siRNAs could efficiently suppress EIF5A2 expression in HGC27 cells (Fig. 1D, E). We used siRNA#1 as EIF5A2-targeted siRNA (T1-siRNA) in the subsequent experiments. EIF5A2 expression was significantly upregulated by transient transfection of EIF5A2 plasmids in MKN45 cells (Fig. 1F, G). T2-siRNA could efficiently suppress MTA1 expression in HGC27 cells (Fig. 1H, I).

EIF5A2 or MTA1 expression levels influenced the aggressiveness of GC cells in vitro
Knockdown of EIF5A2 by T1-siRNA significantly inhibited cell proliferation (Fig. 2A), migration and invasion (Fig. 2B) in HGC27 cells compared with those of the parental cells. Upregulation of EIF5A2 by EIF5A2 plasmid expression promoted increased proliferation (Fig. 2C), migration and invasion (Fig. 2D) of MKN45 cells. Knockdown of MTA1 by T2-siRNA significantly inhibited cell proliferation (Fig. 2E), migration and invasion (Fig. 2F) in HGC27 cells compared with those of the parental cells.

Possible target gene expression after EIF5A2 knockdown or overexpression
After knockdown of EIF5A2 in HGC27 cells, the levels of the epithelial marker E-cadherin were upregulated, while the levels of mesenchymal marker vimentin were downregulated and accompanied by proliferation-related proteins cyclin D1 and cyclin D3 and metastasis-associated C-MYC and MTA1 downregulation (Fig. 3A). In contrast, after EIF5A2 overexpression in MKN45 cells, the expression of E-cadherin was downregulated, while the level of vimentin was
upregulated and accompanied by cyclin D1, cyclin D3, C-MYC and MTA1 upregulation (Fig. 3B). Knockdown or overexpression of EIF5A2 had no significant effect on MMP9 expression in HGC27 and MKN45 cells (Fig. 3A, B).

Association of EIF5A2 and MTA1 expression with clinicopathological features in patients with GC

Positive signals of EIF5A2 were predominantly located in the cytoplasm and nucleus of tumor cells, while MTA1 signals were mainly localized in the nucleus of tumor cells (Fig. 4). We defined the immunostaining values of 0–3 as the normal expression level of EIF5A2 or MTA1, while immunostaining values of 4–12 was defined as overexpression of EIF5A2 or MTA1. EIF5A2 overexpression was found in 75 of the tumor specimens, compared with only seven of 160 matched adjacent non-tumor mucosal tissues (P<0.001). Representative IHC staining of EIF5A2 in moderately- or poorly-differentiated gastric adenocarcinoma, vessel invasion tumor
cells and non-tumor tissue is shown in Fig. 4A, B, C and D, respectively. Of the 160 cases analyzed, 70 (43.75\%) were positive for MTA1. Statistical analysis of the expression patterns showed that there was a positive correlation between EIF5A2 and MTA1 expression (r = 0.510, \( P < 0.001 \)). The typical staining images for overexpression of EIF5A2 and MTA1 in gastric adenocarcinoma were shown in Fig. 4E and 4F.

As shown in Table 1, both EIF5A2 and MTA1 overexpression were positively correlated with more advanced pT stage (\( P = 0.018 \) and \( P = 0.042 \)), pN stage (\( P = 0.037 \) and \( P = 0.020 \))
Fig 3. Immunoblotting analysis of protein expression after silencing or overexpressing EIF5A2 in GC cells. (A) After knockdown of EIF5A2 in HGC27 cells, E-cadherin levels were upregulated, while vimentin was downregulated accompanied by cyclin D1, cyclin D3 and C-MYC, and MTA1 downregulation. (B) Ectopic overexpression of EIF5A2 after transient transfection of EIF5A2-plasmid substantially upregulated cyclin D1, cyclin D3, C-MYC and MTA1, accompanied by downregulation of E-cadherin, while vimentin was upregulated.

doi:10.1371/journal.pone.0119229.g003
and positive lymphovascular invasion ($P = 0.016$ and $P = 0.044$), whereas they were not associated with other clinicopathological features.

**Increased EIF5A2 or MTA1 expression correlated with poorer survival in GC patients**

At the last follow-up, 75 of 160 patients had died. Of these, 73 people died of tumor recurrence. The Kaplan-Meier analysis showed that both the 5-year overall survival (OS) and disease-free survival (DFS) for the EIF5A2 overexpression group were shorter than those for the normal EIF5A2 expression group ($P < 0.001$ and $P = 0.001$, Fig. 4G, H). Consistently, patients with MTA1 overexpression displayed a poor prognosis for OS and DFS ($P < 0.001$ and $P = 0.001$).
Variables with significance in univariate analysis by the Kaplan-Meier methods were included in the multivariate Cox regression analyses. As shown in S1 Table and S2 Table, multivariate analysis identified that overexpression of EIF5A2 was an independent factor influencing both OS (hazard ratio 1.831, 95%CI 1.135 to 2.857, \(P = 0.012\), S1 Table) and DFS (hazard ratio 1.880, 95%CI 1.177 to 3.002, \(P = 0.008\), S2 Table) of patients receiving curative resection for GC. However, the overexpression of MTA1 did not produce independent prognostic significance for OS and DFS in the multivariate analysis.

### Discussion

Eukaryotic initiation factor 5A 2 (EIF5A2) is localized at a chromosomal region often noted for chromosomal instability in GC and many other cancers, 3q.[17–20] EIF5A2, as one of the only two isoforms of EIF5A family, is confirmed as an oncogenic protein and may also be an

| Table 1. Association between EIF5A2 or MTA1 expression and clinicopathological characteristics. |
|-----------------------------------------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| Variables                                    | No. of cases    | EIF5A2 expression | MTA1 expression |                  |                  |                  |
|                                              |                | Normal | Over | \(P\) value | Normal | Over | \(P\) value |                  |                  |                  |
| Gender                                       |                |        |      |            |        |      |            |                  |                  |                  |
| Women                                        | 46             | 23     | 23   | 0.615      | 23     | 23   | 0.311      |                  |                  |                  |
| Men                                          | 114            | 62     | 52   | 0.518      | 67     | 47   | 0.745      |                  |                  |                  |
| Age (years)                                  |                |        |      |            |        |      |            |                  |                  |                  |
| \(\leq 65\)                                  | 96             | 49     | 47   | 0.652      | 53     | 43   | 0.586      |                  |                  |                  |
| \(> 65\)                                     | 64             | 36     | 28   |            | 37     | 27   |            |                  |                  |                  |
| Lauren histotype                             |                |        |      |            |        |      |            |                  |                  |                  |
| Intestinal                                   | 67             | 37     | 30   | 0.293      | 36     | 31   | 0.814      |                  |                  |                  |
| Diffuse-mixed                                | 93             | 48     | 45   |            | 54     | 39   |            |                  |                  |                  |
| Tumor size (cm)                              |                |        |      |            |        |      |            |                  |                  |                  |
| \(\leq 5.0\)                                  | 109            | 61     | 48   | 0.726      | 62     | 47   | 0.675      |                  |                  |                  |
| \(> 5.0\)                                    | 51             | 24     | 27   |            | 28     | 23   |            |                  |                  |                  |
| Tumor location                               |                |        |      |            |        |      |            |                  |                  |                  |
| Upper third                                  | 36             | 18     | 18   | 0.016      | 18     | 18   | 0.044      |                  |                  |                  |
| Middle third                                 | 25             | 12     | 13   |            | 15     | 10   |            |                  |                  |                  |
| Low third                                    | 99             | 55     | 44   |            | 57     | 42   |            |                  |                  |                  |
| LVI                                          |                |        |      |            |        |      |            |                  |                  |                  |
| Present                                      | 57             | 23     | 34   | 0.018      | 26     | 31   | 0.042      |                  |                  |                  |
| Absent                                       | 103            | 62     | 41   |            | 64     | 39   |            |                  |                  |                  |
| pT stage                                     |                |        |      |            |        |      |            |                  |                  |                  |
| T1                                           | 21             | 16     | 5    | 0.037      | 16     | 5    | 0.020      |                  |                  |                  |
| T2                                           | 28             | 19     | 9    |            | 19     | 9    |            |                  |                  |                  |
| T3                                           | 16             | 8      | 8    |            | 10     | 6    |            |                  |                  |                  |
| T4                                           | 95             | 42     | 53   |            | 45     | 50   |            |                  |                  |                  |
| pN stage                                     |                |        |      |            |        |      |            |                  |                  |                  |
| N0                                           | 43             | 29     | 14   | 0.018      | 32     | 11   | 0.042      |                  |                  |                  |
| N1                                           | 38             | 23     | 15   |            | 22     | 16   |            |                  |                  |                  |
| N2                                           | 43             | 18     | 25   |            | 21     | 22   |            |                  |                  |                  |
| N3                                           | 36             | 15     | 21   |            | 15     | 21   |            |                  |                  |                  |

EIF5A2, eukaryotic translation initiation factor 5A2; LVI, lymphovascular invasion; MTA1, Metastasis-associated protein 1.

doi:10.1371/journal.pone.0119229.t001
important biomarker for the prognosis and therapeutic target of many kinds of human tumors. [21] Although a previous study had examined EIF5A2 gene expression in primary GC, the current study provides the first evidence of the clinical significance of EIF5A2 expression in human GC and its possible role in the regulation of GC cell aggressiveness.[22]

We first performed EIF5A2 knockdown and overexpression experiments in vitro. The results showed that suppression of EIF5A2 in HGC27 cells led to significant decreases in cell proliferation, migration and invasion, while its upregulation in MKN45 cells resulted in the converse. These results are consistent with previous findings in other tumors.[8, 10, 23] We also found that MTA1 knockdown in HGC27 cells significantly inhibited cell proliferation, migration and invasion. But the mechanism by which EIF5A2 enhances GC cell aggressiveness is still unknown.

Therefore, we performed further studies of the possible targets of EIF5A2 in vitro. Our results showed that EIF5A2 positively regulated cyclin D1 and cyclin D3, which play important roles in GC cell proliferation and cell cycle regulation.[24, 25] All these results supported the hypothesis that EIF5A2 promotes GC cell proliferation via upregulation of cyclin D1 and cyclin D3. At the same time, previous studies showed that EIF5A2 promotes cell invasion/metastasis and epithelial-mesenchymal transition (EMT) through activating MTA1/C-MYC in colorectal cancer.[8] MTA1 and C-MYC, as well as the EMT program, were also involved in regulation of GC metastasis.[26–28] We therefore examined MTA1, C-MYC and two EMT-associated markers, E-cadherin and vimentin. Our studies demonstrated that EIF5A2 positively regulated MTA1, C-MYC and vimentin and negatively regulated E-cadherin. All these results suggest that EIF5A2 might regulate cell migration and invasion by regulation of MTA1, C-MYC and EMT in vitro, but further studies are required to investigate the exact mechanisms.

The results of the current study also showed that EIF5A2 protein was positively correlated with pT stage and pN stage. Similar results were also observed in human ovarian cancer.[5] These results suggest that EIF5A2 may be associated with tumor invasion and lymph node metastasis in certain types of human cancers, including GC. More interestingly, in the current study, EIF5A2 overexpression was also found in invading cancer cells (vessel invasion), and overexpression of EIF5A2 protein in primary GC tissue correlated with the presence of lymphovascular invasion. In accordance with the results found in previous studies of other human malignancies including epithelial ovarian tumors, bladder carcinoma, lung cancer, and colorectal cancer, overexpression of EIF5A2 in the current study was correlated with poor survival of patients with GC.[5, 8, 29] In addition, multivariate analysis showed that EIF5A2 protein is an independent predictor for poor survival in patients undergoing surgery for GC.

MTA1, as an candidate metastasis-associated gene, have been demonstrated to play the critical role in gastric cancer cell aggressiveness.[27] Overexpression of MTA1 is significantly associated with poor prognosis in pN0 GC patients.[30] The current study showed that EIF5A2 expression was positively correlated with MTA1 expression in human GC tissues. Immunohistochemical analysis combined in vitro studies shown that the EIF5A2-MTA1–axis may play an important role in gastric cancer aggressiveness.

In summary, the results of the current study showed that the overexpression of EIF5A2 was closely related to GC cell proliferation, migration and invasion via metastasis-associated proteins MTA1. At the same time, EIF5A2 may be important in EMT regulation in GC. Overexpression of EIF5A2 could be an independent factor predicting poor survival and an attractive therapeutic target for GC, but further studies are required.

Supporting Information

S1 Table. Analysis of factors associated with overall survival (OS).

(DOC)
S2 Table. Analysis of factors associated with disease-free survival (DFS).

Acknowledgments

The authors would like to thank Mr. De-Tian Wang, Ms. Yu-Feng Luo and Professor Pei Gu for their technical supports.

Author Contributions

Conceived and designed the experiments: QBM WMK JCY. Performed the experiments: QBM WMK YQL ZQM. Analyzed the data: LZ QCC WXZ. Contributed reagents/materials/analysis tools: QBM WMK. Wrote the paper: QBM.

References

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011; 61: 69–90. doi: 10.3322/caac.20107 PMID: 21296855
2. Chen W, Zheng R, Zhang S, Zhao P, Li G, Wu L, et al. Report of incidence and mortality in China cancer registries, 2009. Chin J Cancer Res. 2013; 25: 10–21. doi: 10.3978/j.issn.1000-9604.2012.12.04 PMID: 23732337
3. Bang YJ, Kim YW, Yang HK, Chung HC, Park YK, Lee KH, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet. 2012; 379: 315–321. doi: 10.1016/S0140-6736(11)61873-4 PMID: 22226517
4. Jenkins ZA, Haag PG, Johansson HE. Human eIF5A2 on chromosome 3q25-q27 is a phylogenetically conserved vertebrate variant of eukaryotic translation initiation factor 5A with tissue-specific expression. Genomics. 2011; 71: 101–109.
5. Yang GF, Xie D, Liu JH, Luo JH, Li LJ, Hua WF, et al. Expression and amplification of eIF-5A2 in human epithelial ovarian tumors and overexpression of EIF-5A2 is a new independent predictor of outcome in patients with ovarian carcinoma. Gynecol Oncol. 2009; 112: 314–318. doi: 10.1016/j.ygyno.2009.10.024 PMID: 19054468
6. Ying-Xin W, Ge C, Lei Y, Yu-Pei Z. Expression of Eukaryotic Translation Initiation Factor 5A2 in Pancreatic Adenocarcinoma and Its Correlation with the Prognosis. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2013; 35: 634–638. doi: 10.3881/j.issn.1000-503X.2013.06.009 PMID: 24382241
7. He LR, Zhao HY, Li BK, Liu YH, Liu M, Guan XY, et al. Overexpression of eIF5A-2 is an adverse prognostic marker of survival in stage I non-small cell lung cancer patients. Int J Cancer. 2011; 129: 143–150. doi: 10.1002/ijc.25669 PMID: 20830705
8. Zhu W, Cai MY, Tong ZT, Dong SS, Mai SJ, Liao YJ, et al. Overexpression of EIF5A2 promotes colorectal carcinoma cell aggressiveness by upregulating MTA1 through C-myc to induce epithelial-mesenchymal transition. Gut. 2012; 61: 562–575. doi: 10.1136/gutjnl-2011-300207 PMID: 21813470
9. Tang DJ, Dong SS, Ma NF, Xie D, Chen L, Fu L, et al. Overexpression of eukaryotic initiation factor 5A2 enhances cell motility and promotes tumor metastasis in hepatocellular carcinoma. Hepatology. 2010; 51: 1255–1263. doi: 10.1002/hep.23451 PMID: 20112425
10. Khosravi S, Wong RP, Ardekani GS, Zhang G, Martinka M, Ong CJ, et al. Role of EIF5A2, a downstream target of Akt, in promoting melanoma cell invasion. Br J Cancer. 2013; 110: 399–408. doi: 10.1038/bjc.2013.688 PMID: 24178756
11. Cao D, Huxtin SR, Sui G, Bala P, Sato N, Martin S, et al. Identification of novel highly expressed genes in pancreatic ductal adenocarcinomas through a bioinformatics analysis of expressed sequence tags. Cancer Biol Ther. 2004; 3: 1081–1091. PMID: 15467436
12. Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer. 2011; 14: 101–112. doi: 10.1007/s10120-011-0041-5 PMID: 21573743
13. Hyung WJ, Lee JH, Choi SH, Min JS, Noh SH. Prognostic impact of lymphatic and/or blood vessel invasion in patients with node-negative advanced gastric cancer. Ann Surg Oncol. 2002; 9: 562–567. PMID: 12095972
14. Washington K. 7th edition of the AJCC cancer staging manual: stomach. Ann Surg Oncol. 2010; 17: 3077–3079. doi: 10.1245/s10434-010-1362-z PMID: 20882416
15. Lauren P. The Two Histological Main Types of Gastric Carcinoma: Diffuse and So-Called Intestinal-Type Carcinoma. An Attempt at a Histo-Clinical Classification. Acta Pathol Microbiol Scand. 1965; 64: 31–49. PMID: 14320675

16. Kawasaki G, Yanamoto S, Yoshitomi I, Yamada S, Mizuno A. Overexpression of metastasis-associated MTA1 in oral squamous cell carcinomas: correlation with metastasis and invasion. Int J Oral Maxillofac Surg. 2008; 37: 1039–1046. doi: 10.1016/j.ijom.2008.05.020 PMID: 18640824

17. Guan XY, Fu SB, Xia JC, Fang Y, Sham JS, Du BD, et al. Recurrent chromosome changes in 62 primary gastric carcinomas detected by comparative genomic hybridization. Cancer Genet Cytogenet. 2000; 123: 27–34. PMID: 11120330

18. Schaefer IM, Schuler P, Enders C, Scharf JG, Cameron S, Ramadori G, et al. High chromosomal instability in adenocarcinoma of the ileum arising from multifocal gastric heterotopia with gastritis cystica profunda. Med Oncol. 2011; 28: 1023–1026. doi: 10.1007/s12032-010-9604-2 PMID: 20577832

19. Hu N, Wang C, Ng D, Clifford R, Yang HH, Tang ZZ, et al. Genomic characterization of esophageal squamous cell carcinoma from a high-risk population in China. Cancer Res. 2009; 69: 5908–5917. doi: 10.1158/0008-5472.CAN-08-4622 PMID: 19584285

20. He QJ, Zeng WF, Sham JS, Xie D, Yang XW, Lin HL, et al. Recurrent genetic alterations in 26 colorectal carcinomas and 21 adenomas from Chinese patients. Cancer Genet Cytogenet. 2003; 144: 112–118. PMID: 12850373

21. Wang FW, Guan XY, Xie D. Roles of Eukaryotic Initiation Factor 5A2 in Human Cancer. Int J Biol Sci, 2013; 9: 1013–1020. doi: 10.7150/ijbs.7191 PMID: 24250246

22. Marchet A, Mocellin S, Belluco C, Ambrosi A, DeMarchi F, Mammano E, et al. Gene expression profile of primary gastric cancer: towards the prediction of lymph node status. Ann Surg Oncol. 2007; 14: 1058–1064. PMID: 17106627

23. Zender L, Xue W, Zuber J, Semighini CP, Krasnitz A, Ma B, et al. An oncogenomics-based in vivo RNAi screen identifies tumor suppressors in liver cancer. Cell. 2008; 135: 852–864. doi: 10.1016/j.cell.2008.09.061 PMID: 19012953

24. Zheng L, Qi T, Yang D, Qi M, Li D, Xiang X, et al. microRNA-9 suppresses the proliferation, invasion and metastasis of gastric cancer cells through targeting cyclin D1 and Ets1. PLoS One. 2013; 8: e55719. doi: 10.1371/journal.pone.0055719 PMID: 23383271

25. Song YA, Park YL, Kim KY, Myung E, Chung CY, Cho SB, et al. RON is associated with tumor progression via the inhibition of apoptosis and cell cycle arrest in human gastric cancer. Pathol Int. 2012; 62: 127–136. doi: 10.1111/j.1440-1827.2011.02765.x PMID: 22243783

26. Yang F, Xue X, Bi J, Zheng L, Zhi K, Gu Y, et al. Long noncoding RNA CCAT1, which could be activated by c-Myc, promotes the progression of gastric carcinoma. J Cancer Res Clin Oncol. 2013; 139: 437–445. doi: 10.1007/s00432-012-1324-x PMID: 23143645

27. Toh Y, Oki E, Oda S, Tokunaga E, Ohno S, Maehara Y, et al. Overexpression of the MTA1 gene in gastrointestinal carcinomas: correlation with invasion and metastasis. Int J Cancer. 1997; 74: 459–463. PMID: 9291440

28. Yoo YA, Kang MH, Lee HJ, Kim BH, Park JK, Kim HK, et al. Sonic hedgehog pathway promotes metastasis and lymphangiogenesis via activation of Akt, EMT, and MMP-9 pathway in gastric cancer. Cancer Res. 2011; 71: 7061–7070. doi: 10.1158/0008-5472.CAN-11-1338 PMID: 21975935

29. Chen W, Luo JH, Hua WF, Zhou FJ, Lin MC, Kung HF, et al. Overexpression of EIF5A2 is an independent predictor of outcome in patients of urothelial carcinoma of the bladder treated with radical cystectomy. Cancer Epidemiol Biomarkers Prev. 2009; 18: 400–408. doi: 10.1158/1055-9965.EPI-08-0754 PMID: 19155439

30. Deng X1, Du L, Wang C, Yang Y, Li J, Liu H, et al. Close association of metastasis-associated protein 1 overexpression with increased angiogenesis and poor survival in patients with histologically node-negative gastric cancer. World J Surg. 2013; 37:792–798. doi: 10.1007/s00268-012-1898-0 PMID: 23283219